Turn Therapeutics’ (TTRX) Sell Rating Reiterated at WBB Securities

WBB Securities reiterated their sell rating on shares of Turn Therapeutics (NASDAQ:TTRX) in a research report report published on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

TTRX has been the topic of a number of other reports. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Zacks Research raised Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Finally, Wall Street Zen raised shares of Turn Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Turn Therapeutics has an average rating of “Hold” and an average target price of $9.00.

Turn Therapeutics Stock Up 1.9%

Shares of TTRX opened at $13.72 on Monday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. The company has a 50-day moving average price of $9.99 and a two-hundred day moving average price of $6.49. The stock has a market cap of $408.72 million and a price-to-earnings ratio of -47.31. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Equities analysts predict that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Turn Therapeutics

A number of large investors have recently bought and sold shares of TTRX. Ieq Capital LLC bought a new stake in Turn Therapeutics during the 2nd quarter worth about $1,660,000. Bank of America Corp DE acquired a new stake in shares of Turn Therapeutics in the second quarter valued at approximately $103,000. BlackRock Inc. bought a new position in Turn Therapeutics in the 2nd quarter worth approximately $282,000. Jefferies Financial Group Inc. bought a new position in Turn Therapeutics in the 2nd quarter worth approximately $119,000. Finally, Bridgewater Advisors Inc. acquired a new position in Turn Therapeutics during the 2nd quarter worth $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.